SCHEMBL7459159

SCHEMBL7459159

C1=CC2CCNC2=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28575960 0.86
SCHEMBL28691544 0.77
SCHEMBL7511961 0.70
SCHEMBL28161609 0.66
SCHEMBL28279806 0.66
SCHEMBL31460361 0.65
SCHEMBL312465 0.64
SCHEMBL28399280 0.64
SCHEMBL12466449 0.61
SCHEMBL18339634 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108290055-B Oxime compounds as agonists of the muscle M1 and/or M4 receptor 赫普泰雅治疗有限公司 2021-05-14 CN claimed
CN-108371660-B Application of tetrahydrocyclopentapyrrole compound and derivative thereof 五邑大学 2020-03-10 CN claimed
EP-0680972-B1 Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them ADIR (FR) 2000-03-08 EP claimed
US-5567804-A HUMAN LEUCOCYTE ELASTASE INHIBITOR; ANTIOXIDANT ADIR ET COMPAGNIE (FR) 1996-10-22 US claimed
US-5565429-A HUMAN LEUCOCYTE ELASTASE INHIBITORS; EMPHYSEMA; ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES ADIR ET COMPAGNIE (FR) 1996-10-15 US claimed
EP-0680972-A1 Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them ADIR ET COMPAGNIE (FR) 1995-11-08 EP claimed
US-5190923-A For treatment of neurological disorders such as cognitive disorders ADIR ET COMPAGNIE (FR) 1993-03-02 US claimed
CN-118518439-A Ionic liquid preparation, tissue treatment method and application thereof 清华大学 2024-08-20 CN disclosed
CN-110944992-B Pharmaceutical compounds 赫普泰雅治疗有限公司 2023-05-16 CN disclosed
US-20230014137-A1 COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONIST ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
EP-4066895-A1 COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE OF SAID COMPOUND ONO Pharmaceutical Co., Ltd. (JP) 2022-10-05 EP disclosed
WO-2021107125-A1 COMPOUND HAVING LYSOPHOSPHATIDIC ACID RECEPTOR AGONISTIC ACTIVITY AND PHARMACEUTICAL USE OF SAID COMPOUND 小野薬品工業株式会社 2021-06-03 WO disclosed
CN-108290055-B Oxime compounds as agonists of the muscle M1 and/or M4 receptor 赫普泰雅治疗有限公司 2021-05-14 CN disclosed
EP-0912602-A1 METHOD OF TREATING BETA-AMYLOID PEPTIDE ASSOCIATED CONDITIONS USING TRH ELI LILLY AND COMPANY (US) 1999-05-06 EP disclosed
WO-1997028184-A1 METHOD OF TREATING BETA-AMYLOID PEPTIDE ASSOCIATED CONDITIONS USING TRH ELI LILLY AND COMPANY (US) 1997-08-07 WO disclosed
US-5567804-A HUMAN LEUCOCYTE ELASTASE INHIBITOR; ANTIOXIDANT ADIR ET COMPAGNIE (FR) 1996-10-22 US disclosed
US-5565429-A HUMAN LEUCOCYTE ELASTASE INHIBITORS; EMPHYSEMA; ANTIARTHRITIC AGENTS; RHEUMATIC DISEASES ADIR ET COMPAGNIE (FR) 1996-10-15 US disclosed
EP-0680972-A1 Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them ADIR ET COMPAGNIE (FR) 1995-11-08 EP disclosed
EP-0680972-A1 Trifluoromethylketone peptide derivatives, process for their preparation and pharmaceutical compositions comprising them ADIR ET COMPAGNIE (FR) 1995-11-08 EP disclosed
US-5190923-A For treatment of neurological disorders such as cognitive disorders ADIR ET COMPAGNIE (FR) 1993-03-02 US disclosed